Teva Pharmaceutical Industries (BSP:T1EV34) Long-Term Debt: R$61,961 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
34 GF Score
Price R$86.95
GF Value R$50.71
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Long-Term Debt?

Teva Pharmaceutical Industries BSP:T1EV34 34 Long-Term Debt is R$61,961 Mil as of Jun. 2026. GuruFocus rates BSP:T1EV34 with a GF Score™ of 34/100 and a GF Value™ of R$50.71 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Teva Pharmaceutical Industries's Long-Term Debt for the quarter that ended in Jun. 2026 was R$61,961 Mil.

Teva Pharmaceutical Industries's quarterly Long-Term Debt declined from Dec. 2025 (R$81,759 Mil) to Mar. 2026 (R$73,293 Mil) and declined from Mar. 2026 (R$73,293 Mil) to Jun. 2026 (R$61,961 Mil).

Teva Pharmaceutical Industries's annual Long-Term Debt increased from Dec. 2023 (R$88,985 Mil) to Dec. 2024 (R$97,628 Mil) but then declined from Dec. 2024 (R$97,628 Mil) to Dec. 2025 (R$81,759 Mil).

Teva Pharmaceutical Industries  (BSP:T1EV34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Teva Pharmaceutical Industries Long-Term Debt Related Terms

Teva Pharmaceutical Industries Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Long-Term Debt Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122,241.97 100,202.88 88,985.27 97,628.20 81,759.12

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92,964.25 89,916.06 81,759.12 73,292.84 61,960.62
BSP:T1EV34
34GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of R$61,961 Mil mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Long-Term Debt of R$61,961 Mil as of Jun. 2026.
Is Teva Pharmaceutical Industries' Long-Term Debt too high?
Teva Pharmaceutical Industries' current Long-Term Debt is R$61,961 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Long-Term Debt compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Long-Term Debt of R$61,961 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Teva Pharmaceutical Industries's current Long-Term Debt is R$61,961 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$50.71, compared to a current price of R$86.95 — trading 71.5% above its estimated fair value. The current Long-Term Debt is R$61,961 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Long-Term Debt is R$61,961 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$86.95 is trading 71.5% above its estimated GF Value™ of R$50.71. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for BSP:T1EV34:

  • Long-Term Debt: R$61,961 Mil
  • GF Value™: R$50.71 vs. price of R$86.95 (71.5% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
34GF Score

Get the complete analysis for BSP:T1EV34

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$86.95
Price
R$50.71
GF Value